Canephron® N — proven efficiency and reasonable alternative to antibiotics in treatment of uncomplicated urinary tract infections

September 4, 2019
949
Resume

Urinary tract infections are among the most common dise­ases in society. The antibacterial therapy is not always justified and contributes to the formation of antibiotic resistance. At the same time, the use of herbal drugs, such as Canephron® N, has shown high efficacy in the treatment of urinary tract infections, in particularly uncomplicated.

References:

  • Bell B.G., Schellevis F., Stobberingh E. et al. (2014) A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect. Dis., 9(4): 13.
  • Bleidorn J., Hummers-Pradier E., Schmiemann G. et al. (2016) Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial. Ger. Med. Sci., 14: Doc01.
  • European Association of Urology (2018) Urological Infections (http://www.http://uroweb.org/ guideline/urological-infections).
  • Ferry S.A., Holm S.E., Stenlund H. et al. (2004) The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand. J. Infect. Dis., 36: 296–301.
  • Flores-Mireles A.L., Walker J.N., Caparon M. et al. (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol., 13(5): 269–284.
  • Foxman B. (2010) The epidemiology of urinary tract infection. Nat. Rev. Urol., 7: 653–660.
  • Hulscher M.E., Grol R.P., van der Meer J.W. (2010) Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect. Dis., 10(3): 167–175.
  • Ivanov D., Abramov-Sommariva D., Moritz K. et al. (2015) An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clin. Phytosci. J. Phytomed. Phytother., 1: 7.
  • Johansen T.E., Botto H., Cek M. et al. (2011) Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int. J. Antimicrob. Agents, 38 Suppl.: 64–70.
  • Kranz J., Schmidt S., Lebert C. et al. (2018) The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol. Int., 100: 263–270.
  • Kronenberg A., Butikofer L., Odutayo A. et al. (2017) Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ, 359: j4784.
  • Künstle G., Brenneis C., Pergola C., et al. (2013) Anti-inflammatory effects of Canephron® N and effectiveness in a model of interstitial cystitis. Urologe, 52 (Suppl. 1): e97.
  • Miotla P., Wawrysiuk S., Naber K. et al. (2018) Should we always use antibiotics after urodynamic studies in high-risk patients? (https://www.hindawi.com/journals/bmri/2018/1607425/).
  • MSD Manual. Professional Version (2018) Introduction to Urinary Tract Infections (UTIs) (https://www.msdmanuals.com/professional/genitourinary-disorders/urinary-tract-infections-utis/introduction-to-urinary-tract-infections-utis).
  • Naber K., Steindl H., Abramov-Sommariva D., Eskötter H. (2013) Non-antibiotic herbal therapy of uncomplicated lower urinary tract infection in women — a pilot study. Planta Med., 79: PB1.
  • Naber K.G., Kogan M., Wagenlehner F.M.E. et al. (2017) How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. Clin. Phytosci. Int. J. Phytomed. Phytother., 3: 8.
  • Nicolle L.E., Bradley S., Colgan R. et al. (2005) Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin. Infect. Dis., 40(5): 643–654.
  • Nielubowicz G.R., Mobley H.L. (2010) Host-pathogen interactions in urinary tract infection. Nat. Rev. Urol., 7(8): 430–441.
  • Saleh A.A., Aldayyen A., Yenina K. et al. (2019) Optimization of antibiotic selection in the emergency department for urine culture follow ups, a retrospective pre-post intervention study: clinical pharmacist efforts. J. Pharmaceut. Pol. Pract., 12: 8.
  • Schappert S.M., Rechtsteiner E.A. (2011) Ambulatory medical care utilization estimates for 2007. Vital. Health Stat., 13: 1–38.
  • Stamm W.E., Norrby S.R. (2001) Urinary tract infections: disease panorama and challenges. J. Infect. Dis., 183 (Suppl. 1): S1–S4.
  • Storme O., Tirán Saucedo J., Garcia-Mora A. (2019) Risk factors and predisposing conditions for urinary tract infection. Ther. Adv. Urol., 2(11): 1756287218814382.
  • Tandogdu Z., Cek M., Wagenlehner F. et al. (2014) Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J. Urol., 32: 791–801.
  • Wagenlehner F.M., Abramov-Sommariva D., Höller M. et al. (2018) Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol. Int., 101(3): 327–336.
  • Wagenlehner F.M., Pilatz A., Naber K.G. et al. (2008) Therapeutic challenges of urosepsis. Eur. J. Clin. Investig., 38 (Suppl. 2): 45–49.